A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen

HIV Clinical Trials

Volumn 11, Issue 6, 2010, Pages 312-324

  Hammer, Scott M ^a   Ribaudo, Heather ^b   Bassett, Roland ^c   Mellors, John W ^d   Demeter, Lisa M ^e   Coombs, Robert W ^f   Currier, Judith ^g   Morse, Gene D ^h   Gerber, John G ⁱ   Martinez, Ana I ^j   Spreen, William ^k   Fischl, Margaret A ^l   Squires, Kathleen E ^m  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF ROCHESTER   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY AT BUFFALO   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k GLAXOSMITHKLINE   (United States)

^l UNIVERSITY OF MIAMI   (United States)

^m THOMAS JEFFERSON UNIVERSITY   (United States)

more..

Author keywords

abacavir; antiretroviral therapy; intensification

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATINE KINASE; INDINAVIR; LAMIVUDINE; PLACEBO; STAVUDINE; TRIACYLGLYCEROL; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ABNORMAL LABORATORY RESULT; ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CEREBROVASCULAR ACCIDENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; NEUROLOGIC DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; VIREMIA; VIRUS MUTATION;

ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDEOXYNUCLEOSIDES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; PLACEBOS; TREATMENT FAILURE; YOUNG ADULT; ZIDOVUDINE;

EID: 78751559513     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1105-312     Document Type: Article

References (43)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. December 1, 2009;1-161. AdultandAdolescentGL.pdf. Accessed July 23, 2010.
2. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321-333.
3. Demeter LM, Hughes MD, Coombs RW, et al. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Ann Intern Med. 2001;135(11):954-964.
4. Fang CT, Chang YY, Hsu HM, et al. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. Q J Med. 2007;100(2):97-105.
5. Degen O, van Lunzen J, Stellbrink HJ. Intensifi cation of background antiretroviral therapy with abacavir during low-level failure may restore optimal suppression. Antivir Ther. 2000;5(2):91-94.
6. Gulick RM, Lalama CM, Ribaudo HJ, et al. Intensifi cation of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS. 2007;21(7):813-823.
7. Katlama C, Clotet B, Plettenberg A, et al. Intensifi cation of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial. HIV Med. 2001;2(1):27-34.
8. Khanlou H, Guyer B, Farthing C. Efficacy of tenofovir as intensification of zidovudine/lamivudine/abacavirfixed-dose combination in the treatment of HIV-positive patients. J Acquir Immune Defi c Syndr. 2005;38(5):627-628.
9. Squires K, Pozniak AL, Pierone G Jr, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med. 2003;139(5 Pt 1):313-320.
10. 4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725-733.
11. Krieger JN, Nirapathpongporn A, Chaiyaporn M, et al. Vasectomy and human immunodefi ciency virus type 1 in semen. J Urol. 1998;159(3):820-5; discussion 5-6.
12. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA. 1997;94(24):13193-13197.
13. Finzi D, Hermankova M, Pierson T, et al. Identifi cation of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278(5341):1295-1300.
14. 4+ T cells. J Virol. 2006;80(13):6441-6457.
15. Gunthard HF, Frost SD, Leigh-Brown AJ, et al. Evolution of envelope sequences of human immunodefi ciency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol. 1999;73(11):9404-9412.
16. Kulkosky J, Sullivan J, Xu Y, et al. Genotypic alteration of HAART-persistent HIV-1 reservoirs in vivo. Virology. 2003;314(2):617-629.
17. Lambotte O, Chaix ML, Gubler B, et al. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS. 2004;18(8):1147-1158.
18. Persaud D, Ray SC, Kajdas J, et al. Slow human immunodefi ciency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res Hum Retroviruses. 2007;23(3):381-390.
19. Siliciano JD, Siliciano RF. A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother. 2004;54(1):6-9.
20. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278(5341):1291-1295.
21. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340(21):1605-1613.
22. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfi navir for the initial treatment of HIV infection. N Engl J Med. 2002;346(26):2039-2046.
23. DiCenzo R, Forrest A, Squires KE, et al. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodefi ciency virus-infected patients. Antimicrob Agents Chemother. 2003;47:1929-1935.
24. D:A:D Study Group, Sabin CA, Worm SW, et l. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371(9622):1417-1426.
25. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk acroiss 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defi c Syndr. 2009;51(1):20-28.
26. Havlir DV, Strain MC, Clerici M, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodefi ciency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol. 2003;77(20):11212-11219.
27. Ramratnam B, Ribeiro R, He T, et al. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defi c Syndr. 2004;35(1):33-37.
28. Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 2007;3(4):e46.
29. Fischl MA, Ribaudo HJ, Collier AC, et al. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodefi ciency virus disease. J Infect Dis. 2003;188(5):625-634.
30. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA. 2006;296(7):769-781.
31. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349(24):2293-2303.
32. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349(24):2304-2315.
33. Yeni P, Cooper DA, Aboulker JP, et al. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet. 2006;368(9532):287-298.
34. Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensifi cation on low-level residual viremia in HIVinfected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 2010:7:e10000321.
35. McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensifi cation does not reduce persistent lowlevel viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010;50:912-919.
36. Wiegand A, Cossarini F, Poethke C, et al. Raltegravir intensification does not reduce persistent HIV-1 viremia in treatment-experienced patients. In: Program and abstracts from the 17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco. Abstract 280.
37. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravircontaining intensifi cation on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010;24:2451-2460.
38. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensifi cation of HAART-suppressed subjects. Nat Med. 2010;16:460-465.
39. Evering T, Mehandru S , Poles M, et al. Antiviral and immunological effects of intensifi cation of suppressive ART with maraviroc, a CCR5 antagonist. In: Program and abstracts from the 17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco. Abstract 283.
40. Gutierrez C, Diaz L, Hernandez-Novoa B, et al. Effect of the intensifi cation with a CCR5 antagonist on the decay of the HIV-1 latent reservoir and residual viremia. In: Program and abstracts from the 17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco. Abstract 284.
41. 4+ cell response despitesustained virologic suppression: ACTG 5256. In: Program and abstracts from the 17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco. Abstract 285.
42. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science. 2009;323(5919);1304-1307.
43. 4+ cell function. PLoS ONE. 2010;5:e9390.